Emcure Pharma Share Price Target 2025, 2026, 2030, 2040, 2050

Emcure Pharmaceuticals is an Indian medicine company that makes good-quality, affordable medicines for many long-term health problems like heart issues, cancer, diabetes, HIV, and women’s health. The company makes many types of medicines, such as tablets, syrups, injections, special drug ingredients (APIs), and advanced biologic medicines, and sells them in India and in more than 70 countries. It has 13 factories and 5 research centres in India, where it works on new ideas to make better treatments.

What is Emcure Pharmaceuticals Ltd NSE: EMCURE?

Emcure Pharmaceuticals was established in 1981 in Pune by Satish Mehta. It is an Indian medicine company that makes and sells many kinds of medicines in India and in over 70 countries. The company makes medicines for women’s health, heart problems, cancer, HIV, infections, diabetes, and many other health issues. It produces tablets, capsules, injections, biologics, and other advanced medicines in its many factories across India. It has slowly grown from a small company into a major international pharma brand with strong research, modern technology, and a growing global presence.

Emcure Pharma Share Price Target

Emcure Pharma Share Price Target 2025

The company began very small, with the simple aim of making good-quality medicines for people in India. Over time, it slowly grew from a small manufacturing unit into a big pharmaceutical company. In the early years, it focused on learning how to make medicines properly, building strong systems, and earning trust in the healthcare field. This strong beginning helped it grow into one of India’s top pharma companies with a presence in many countries. In 2025, its share price target would be ₹1600, as per stock market analysts.

According to stock market analysts, its share price would be between ₹889 to ₹1600 in 2025.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	889	1600

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	1110	1491
February	941	1310
March	910	1082
April	889	1140
May	983	1412
June	1285	1430
July	1228	1458
August	1317	1519
September	1260	1409
October	1260	1448
November	1306	1463
December	1272	1600

Emcure Pharma Share Price Target 2026

It works in many important health areas such as women’s health, heart problems, blood disorders, cancer, diabetes, HIV, vitamins, and infection control. It makes many types of medicines like tablets, syrups, injections, biologics, and complex APIs. Because of this wide range, doctors have many choices to treat different health issues. This also helps it serve many kinds of patients, from those with simple problems to those with serious or long-term diseases. In 2026, its share price target would be ₹2676, as per stock market analysts.

According to stock market analysts, its share price would be between ₹1574 to ₹2676 in 2026.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2026	1574	2676

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	1574	1753
February	1590	1835
March	1662	1858
April	1682	1935
May	1752	2045
June	1812	2084
July	1856	2153
August	1935	2184
September	2025	2256
October	2074	2365
November	2125	2487
December	2357	2676

Share Price Target 2027

This company has 13 manufacturing plants and 5 research centres in India. These centres help the company make new medicines, test new ideas, and produce drugs in large quantities. It ensures its medicines are safe and reliable with modern machines, skilled scientists, and strict quality checks. This strong setup helps the company make everything from simple tablets to advanced biologics. Having all these facilities also helps Emcure stay competitive and continue improving. In 2027, its share price target would be ₹3181, as per stock market analysts.

According to stock market analysts, its share price would be between ₹2625 to ₹3181 in 2027.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2027	2625	3181

Share Price Target 2028

In the beginning, it mostly made medicines for other big international pharma companies. But later, it changed its direction and started making its own products. This helped the company build its own brand, develop strong research abilities, and control everything from production to marketing. This change helped the company grow into a respected and independent pharmaceutical leader, trusted by doctors and patients. In 2028, its share price target would be ₹3700, as per stock market analysts.

According to stock market analysts, its share price would be between ₹3142 to ₹3700 in 2028.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2028	3142	3700

Share Price Target 2029

It is known for making advanced medicines like biologics, complex APIs, and special formulations. These kinds of products need high skills, advanced technology, and strong scientific knowledge. By investing in these areas, Emcure entered the field of speciality medicines, which includes treatments for cancer, rare diseases, and serious infections. This gives the company an advantage over companies that only make basic, generic medicines. In 2029, its share price target would be ₹4168, as per stock market analysts.

According to stock market analysts, its share price would be between ₹3652 to ₹4168 in 2029.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2029	3652	4168

Emcure Pharma share price Target 2030

In India, it is a leader in women’s health and HIV treatment. Doctors trust the company because it has been making reliable medicines for many years. Its strong presence in different therapy areas helps it stay stable even when the demand for some medicines goes up or down. Its leadership shows the company’s quality, value, and long-term trust among healthcare professionals. In 2030, its share price target would be ₹4955, as per stock market analysts.

According to stock market analysts, its share price would be between ₹4120 to ₹4955 in 2030.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2030	4120	4955

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	4120	4332
February	4174	4384
March	4211	4420
April	4250	4478
May	4278	4512
June	4332	4580
July	4357	4635
August	4384	4675
September	4425	4758
October	4525	4790
November	4575	4825
December	4678	4955

Share Price Target 2040

It is also known for bringing new and advanced medicines to the Indian market. It has launched many first-of-their-kind products, including special iron medicines, biologics, and improved formulations. This focus on new ideas helps it to stand out from companies that only make regular, generic drugs. It supports patients who need better and more effective treatment options by offering unique medicines early. In 2040, its share price target would be ₹9567, as per stock market analysts.

According to stock market analysts, its share price would be between ₹8401 to ₹9567 in 2040.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2040	8401	9567

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	8401	8620
February	8451	8668
March	8474	8689
April	8535	8720
May	8589	8742
June	8635	8832
July	8675	8874
August	8745	8961
September	8820	9154
October	8936	9256
November	9057	9384
December	9224	9567

Share Price Target 2050

It works with many international partners to develop, make, and sell medicines around the world. These partnerships help the company get new technologies, better production methods, and new ideas for treatments. Through such collaborations, it is able to offer advanced therapies at affordable prices in developing countries. These global partnerships also strengthen its presence and build long-lasting trust. In 2050, its share price target would be ₹14000, as per stock market analysts.

According to stock market analysts, its share price would be between ₹12900 to ₹14000 in 2050.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2050	12900	14000

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	12900	13204
February	13010	13357
March	13077	13384
April	13175	13458
May	13235	13562
June	13275	13663
July	13368	13690
August	13458	13744
September	13558	13780
October	13622	13853
November	13715	13921
December	13852	14000

Should I buy Emcure Pharma stock?

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	889	1600
2026	1574	2676
2027	2625	3181
2028	3142	3700
2029	3652	4168
2030	4120	4955
2040	8401	9567
2050	12900	14000

It could be a good choice for people who want to invest for the medium or long term because the company is growing well, earning more revenue and profit, and selling medicines in India and other countries. But the stock can go up and down, and there are risks like competition and government rules. So, it may be suitable for investors who are okay with some ups and downs and believe the company will grow over time. People who want very safe or short-term investments should be careful.

Emcure Pharma earnings results

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales +	5,049	5,033	5,855	5,986	6,658	7,896	8,449
Expenses +	4,340	3,817	4,525	4,804	5,429	6,427	6,793
Operating Profit	708	1,216	1,330	1,182	1,230	1,469	1,656
OPM %	14%	24%	23%	20%	18%	19%	20%
Other Income +	-25	-159	63	39	47	62	-6
Interest	257	155	176	214	237	176	130
Depreciation	321	250	245	260	312	384	398
Profit before tax	105	652	973	747	727	971	1,123
Tax %	4%	36%	28%	25%	27%	27%
Net Profit +	101	419	703	562	528	707	819
EPS in Rs	4.62	23.15	36.62	29.42	27.50	35.96	41.84
Dividend Payout %	54%	4%	8%	7%	7%	8%

Key Metrics

TTM PE Ratio	PB Ratio	Dividend Yield	Sector PE	Sector PB	Sector Div Yld
33.37	5.70	0.21%	36.87	5.82	0.59%

Peers & Comparison

Stock	PE Ratio	PB Ratio	Dividend Yield
Emcure Pharmaceuticals Ltd	38.85	5.70	0.21%
Sun Pharmaceutical Industries Ltd	39.63	5.98	0.89%
Torrent Pharmaceuticals Ltd	67.04	16.88	0.85%
Cipla Ltd	23.30	3.93	1.05%

Is Emcure Pharma stock good to buy? (bull case & bear case)

Bull Case:

• In Q4 FY25, its revenue rose about 19.5% compared to last year, reaching ₹2,116 crore.
• Profit after tax (PAT) in Q4 FY25 increased aby bout 63% from last year, reaching around ₹197 crore.
• EBITDA in Q4 FY25 grew about 25% year-on-year, and the EBITDA margin improved to around 18.4–19.0%, showing better efficiency.
• For the full year FY25, total revenue was about ₹7,896 crore, up from ₹6,658 crore in FY24 (18.6% growth), and PAT was about ₹707 crore, up from ₹528 crore in FY24 (34% rise).
• Revenue growth comes from both domestic business (around ₹929 crore in Q4 FY25) and international business (around ₹1,187 crore), showing the company earns from multiple sources.

Bear Case:

• Comparing quarter to quarter, Q3 FY25 revenue was about ₹1,962 crore, and net profit was about ₹153.7 crore, which shows some ups and downs in performance.
• Gross profit margin in Q4 FY25 was about 57.8%, down from 62.1% last year, meaning the costs of making medicines are rising.
• The pharma industry has strong competition, pricing pressure, and strict rules, which can reduce profits.
• To keep growing, the company must keep launching new medicines, maintain demand in India and abroad, and control costs — any slip-ups could affect results.

Conclusion

It is an Indian medicine company. It makes many types of affordable and good-quality medicines for health problems like heart disease, cancer, diabetes, HIV, and women’s health. The company has several factories and research centres where it makes tablets, syrups, injections, biologics, and other medicines, and sells them in India and many other countries. It has grown steadily over the years and is known for new ideas, strong research, and its presence worldwide. Its stock may be good for long-term investors, but it has risks like competition, rules, and market changes.

FAQs